Table 3

Change in IOP (mmHg) from baseline to week 4 (worse eye, ANCOVA, ITT population using LOCF)
Latanoprost concentration (μg/mL)
50 75 100 125
N 71 70 72 69
8 a.m. IOP
 LS mean change (mmHg)* −9.72 −9.49 −10.04 −9.23
 Adjusted difference in LS mean ± SEM 0.23 ± 0.58 −0.32 ± 0.58 0.49 ± 0.58
 (90% CI) (−0.72, 1.19) (−1.27, 0.63) (−0.47, 1.45)
 p-value 0.657 0.289 0.802
4 p.m. IOP
 LS mean change (mmHg)* −8.47 −7.96 −8.84 −8.49
 Adjusted difference in LS mean ± SEM 0.51 ± 0.63 −0.36 ± 0.62 −0.02 ± 0.63
 (90% CI) (−0.53, 1.55) (−1.39, 0.67) (−1.06, 1.02)
 p-value 0.792 0.280 0.488

ANCOVA analysis of covariance, CI confidence interval, IOP intraocular pressure, LS least square, ITT intent to treat, SEM standard error of the mean.

*Adjusting for baseline IOP (covariate) with dose group and center as factors.

Higher concentration minus latanoprost 50 μg/mL; a negative difference in LS mean indicates that the higher concentration has a greater effect than latanoprost 50 μg/mL.

One-sided p-value.

Eveleth et al.

Eveleth et al. BMC Ophthalmology 2012 12:9   doi:10.1186/1471-2415-12-9

Open Data